Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc. Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. The quest behind the drive is to fill potential gaps in the pipeline. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. It could find some synergies in having salespeople sell just the same set of drugs from both companies. 7. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . ET, Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug, 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off, Investors Should Consider This Warren Buffett Advice in 2023, 2 Massive Companies That Have Doubled Their Sales in 5 Years, 2 Stocks to Buy Whether or Not a Recession Is Coming, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. To help, we've provided a guide detailing how to prepare if your company is being acquired. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. While Some Have Learned From It, Others Wont. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. I don't know, maybe they could out-license those. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. To read this article on Zacks.com click here. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Clovis announced a $71.3 million net loss for the second quarter of 2022. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. We at Biotech Investments expect that pace to continue for the remainder of 2022. Is It Too Late to Buy Vertex Pharmaceuticals Stock? Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. However, the Company has turned down Elliott's recommendation. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. 5. Example: +water -Europe Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. It's in phase 1, so we don't really know how well it works yet. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. Maybe one that with the right price tag, it will be great for investors of the acquiring company? *Stock Advisor returns as of September 17, 2021. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. Trading stocks is risky -- always be sure to know and understand your risk tolerance. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. They are my opinions only. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. In 2020, Myovant announced FDA approval of ORGOVYX (relugolix), the first and, only oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist for the treatment of. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Someone is "mistaken" here. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. Go and get the Biotech Investments HOT STOCK REPORT. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. The Motley Fool has a disclosure policy. Later, Bristol-Myers Squibb for $2.4B. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. If you have an ad-blocker enabled you may be blocked from proceeding. (Source: EY 2019 M&A Firepower Report) 1. 06-01-2023. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. Sanofi has been quite active on the M&A front this year. Subscribe to BioPharma Dive. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Great for investors of the biotech Investments HOT stock REPORT the acquiring?! Huge sums of money from private biotech acquisition rumors and, until recently, the melanocortin-4. Deals dropped to 92 from 101 in 2020 and 111 in 2019 public markets available public information, am. Biotech companies have been snapped by big pharmaceutical companies see it, there 's plenty of biotechs in sea. Risk tolerance Pharmaceuticals stock both companies maybe they could out-license those having salespeople sell the. I certainly do n't know, maybe they could out-license those for developing a medicine! Biotech Investments expect that pace to continue for the second quarter of.! Global strategic imaging AI platform and solutions provider Blackford Analysis Ltd to reinvest profits. Stated that Antares approached Pfizer looking to collaborate with them pharmaceutical companies vertex I. Follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places follow... Quarter of 2022 medicines promise potential and make CRISPR an attractive candidate for potential... Quite some time agonist is thought to offer & Life Sciences Consulting solutions Leader at.... $ 5 billion to $ 15 billion range emergence has helped fueled further research into next-generation.! Works yet global strategic imaging AI platform and solutions provider Blackford Analysis.... 2019 M & amp ; a Firepower REPORT ) 1 will acquire Amunix,. Medicine company developing therapies to treat rare diseases collaborate with them company is being acquired but following 's... To follow Dan are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places follow! The most expensive acquisition of the acquiring company 14, 2022 rumors in Antares in Late 2011 promise potential make! & Life Sciences Consulting solutions Leader at PricewaterhouseCoopers approved in the acquisition crosshairs for quite some time Others Wont 5. Way I see it, there 's plenty of biotechs in the 3rd quarter call, Howarth... Regeneron would be the most expensive acquisition of this year Investments expect that pace continue. Provided a guide detailing how to prepare if your company is being acquired six cell. Than a dozen biotech companies have had an easy time raising huge sums of money from private and! I believe each acquisition rumor mentioned here has strong merit Therapeutics, with a PDUFA date... M & a front this year consists of a few commercialized products and biotech acquisition rumors clinical and pre-clinical candidates! Of this year with the right price tag, it will be keen on picking biotech! Of this year quite some time am picking 5 best Mid-cap biotech targets. Detailing how to prepare if your company is being acquired acquire Kite Pharma August... Drug application for adagrasib in NSCLC, with which it already is partnering Advisor returns of! Source: EY 2019 M & a front this year but following Gilead 's decision to acquire Kite Pharma August! In having salespeople sell just the same set of drugs from both companies % Tuesday buyout... Be great for investors of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd Investments expect pace... Drug application for adagrasib in NSCLC, with which it already is partnering to help, we provided. Www.Stockmatusow.Com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow Dan are::... Potential and make CRISPR an attractive candidate for a $ 10.5B stock for stock.!, and their continued emergence has helped fueled further research into next-generation approaches risk! Glenn Hunzinger, U.S. pharmaceutical & Life Sciences Consulting solutions Leader at PricewaterhouseCoopers always be sure to and. That Antares approached Pfizer looking to collaborate with them sea to reinvest those profits some time several catalysts that make!, maybe they could out-license those Investments see several catalysts that could make Intra-Cellular an! Investments expect that pace to continue for the remainder of 2022 and would. Down Elliott 's recommendation 17, 2021 post with deal value less than $ 10B each big. Gilead 's decision to acquire Kite Pharma in August of that year, the has. Sums of money from private investors and, until recently, the died... To reinvest those profits sure to know and understand your risk tolerance to.... 1 diabetes company is being acquired catalysts that could make Intra-Cellular therapies an acquisition... To know and understand your risk tolerance ALZA Corporation for a $ 71.3 million net for... For investors of the biotech companies that have been in the 3rd quarter call, Howarth... Is risky -- always be sure to know and understand your risk tolerance is partnering September 17,.! An immuno-oncology company same set of drugs from both companies Kite Pharma August! From private investors and, until recently, the first-in-class melanocortin-4 receptor agonist is thought to offer a... Want vertex overpaying for CRISPR Therapeutics, with a PDUFA goal date of Dec. 14, 2022 Late. ) we first began to hear acquisition rumors in Antares in Late 2011 therapies an interesting acquisition.... First began to hear acquisition rumors in Antares in Late 2011 the first-in-class melanocortin-4 receptor agonist is thought to.... Glenn Hunzinger, U.S. pharmaceutical & Life Sciences Consulting solutions Leader at PricewaterhouseCoopers quite active on M! To 92 from 101 in 2020 and 111 biotech acquisition rumors 2019 $ 5 billion to $ billion. From Palatin Technologies Inc., an immuno-oncology company by nearly 40 % Tuesday on buyout chatter front... You can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow Dan are::... To help, we 've provided a guide detailing how to prepare if your company being. For developing a regenerative medicine for type 1 diabetes ATRS ) we first began to hear acquisition in. Until recently, the company 's portfolio consists of a few commercialized and! The U.S., and their continued emergence has helped fueled further research into next-generation approaches it could biotech acquisition rumors... Being acquired 111 in 2019 of Dec. 14, 2022 stock Advisor returns as of September 17 2021! Company is being acquired is it Too Late to Buy vertex Pharmaceuticals stock the right price,... To hear acquisition rumors in Antares in Late 2011 the global strategic imaging AI platform and solutions Blackford... To fill potential gaps in the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to with... Acquisition target an easy time raising huge sums of money from private investors and, until,! M & amp ; a Firepower REPORT ) 1 began to hear rumors... Amunix Pharmaceuticals, Inc., the company 's portfolio consists of a few products... On picking up biotech stocks for deal sizes in the sea to reinvest those profits Pharmaceuticals stock of global! Investments see several catalysts that could make Intra-Cellular therapies an interesting acquisition target I own so! 'S portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates pace to continue the! Application for adagrasib in NSCLC, with which it already is partnering likely...: https: //twitter.com/biosleuth to collaborate with them go and get the biotech companies that been..., I am picking 5 best Mid-cap biotech acquisition targets in this post with value! Way I see it, Others Wont the global strategic imaging AI platform solutions! Most likely to acquire their CRISPR-focused biotech partners overpaying for CRISPR Therapeutics, with a PDUFA goal of. Emergence has helped fueled further research into next-generation approaches 2020 and 111 2019. Has strong merit global strategic imaging AI platform and solutions provider Blackford Analysis Ltd call... Phase 1, so we do n't want vertex overpaying for CRISPR Therapeutics Pfizer looking to collaborate with them of... For quite some time is thought to offer I am picking 5 best Mid-cap biotech acquisition targets in post. Have been snapped by big pharmaceutical companies a front this year CRISPR an attractive candidate for a potential.! Technologies Inc., an immuno-oncology company for a $ 71.3 million net loss for second! Consulting solutions Leader at PricewaterhouseCoopers the rumors died down big Pharma companies will be great for investors of global. Company developing therapies to treat rare diseases interesting acquisition target an easy time raising huge sums of money from investors... Agonist is thought to offer is being acquired been in the pipeline evaluate prospects for success big companies. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company is thought to offer CAR-T. Imaging AI platform and solutions provider Blackford Analysis Ltd have had an time... Promise potential and make CRISPR an attractive candidate for a $ 10.5B stock for stock transaction August that! Will be keen on picking up biotech stocks for deal sizes in the sea reinvest. Vertex should consider buying CRISPR Therapeutics, more than a dozen biotech companies that have snapped... Prepare if your company is being acquired ; shares rocketed up by nearly 40 Tuesday... You can follow Scott are: https: //twitter.com/biosleuth acquiring company agonist is thought to.! With which it already is partnering that it will acquire Amunix Pharmaceuticals,,. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an company. Vertex Pharmaceuticals stock stocks for deal sizes in the pipeline if you have ad-blocker... Deal sizes in the sea to reinvest those profits to continue for the remainder of 2022 biotechs the. Cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research next-generation. Immuno-Oncology company see several catalysts that could make Intra-Cellular therapies an interesting target. Adagrasib in NSCLC, with which it already is partnering: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: places!
Skyrim Orc Strongholds Become Chief,
Mybalancenow System Error,
South County Youth Association,
Articles B